0001209191-22-050525.txt : 20220919 0001209191-22-050525.hdr.sgml : 20220919 20220919163015 ACCESSION NUMBER: 0001209191-22-050525 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220919 FILED AS OF DATE: 20220919 DATE AS OF CHANGE: 20220919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCIASCIA THOMAS CENTRAL INDEX KEY: 0001229946 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38886 FILM NUMBER: 221250907 MAIL ADDRESS: STREET 1: 39 OLD RIDGEBURY RD. SUITE 11 CITY: DANBURY STATE: CT ZIP: 06810 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Trevi Therapeutics, Inc. CENTRAL INDEX KEY: 0001563880 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450834299 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 195 CHURCH STREET STREET 2: 14TH FLOOR CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-304-2499 MAIL ADDRESS: STREET 1: 195 CHURCH STREET STREET 2: 14TH FLOOR CITY: NEW HAVEN STATE: CT ZIP: 06510 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-19 0 0001563880 Trevi Therapeutics, Inc. TRVI 0001229946 SCIASCIA THOMAS C/O TREVI THERAPEUTICS, INC. 195 CHURCH STREET, 14TH FLOOR NEW HAVEN CT 06510 0 1 0 0 Chief Medical Officer Performance Stock Options (right to buy) 3.21 2022-09-19 4 A 0 7500 0.00 A 2022-09-19 2031-02-16 Common Stock 7500 37500 D Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 37,500 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. On September 19, 2022, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the CANAL trial were satisfied, resulting in the vesting of the option as to the 7,500 shares of common stock. /s/ Christopher Galletta, attorney-in-fact 2022-09-19